All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Intensified Frontline ABVD Improves PFS in Advanced Classical Hodgkin Lymphoma

July 10th 2023

Dose-dense and dose-intense doxorubicin, bleomycin, vinblastine, dacarbazine, and granulocyte colony–stimulating factor (ABVD) generated an improvement in progression-free survival and other efficacy end points compared with PET-adapted ABVD in previously untreated patients with advanced classical Hodgkin lymphoma.

THIO Followed by Cemiplimab Shows Early Promise in Advanced NSCLC

July 10th 2023

The sequential combination of 6-thio-2’-deoxyguanosine and cemiplimab provided a progression-free survival benefit in the first 2 patients with advanced non–small cell lung cancer enrolled to the part A safety lead-in portion of the phase 2 THIO-101 trial.

Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast Cancer

July 10th 2023

Nancy U. Lin, MD, provides clinical insights on the treatment of patients with breast cancer brain metastases and discusses the advantages and disadvantages of systemic therapy vs radiation therapy for this population.

Neoadjuvant Enfortumab Vedotin Continues to Elicit Encouraging Antitumor Activity in MIBC

July 10th 2023

Single-agent enfortumab vedotin in the neoadjuvant setting had substantial antitumor activity and a high event-free survival rate with a manageable toxicity profile in patients with cisplatin-ineligible muscle-invasive bladder cancer.

PRT811 Showcases Early Signals of Efficacy in IDH-Mutant Glioma and Uveal Melanoma

July 10th 2023

Varun Monga, MBBS, discusses the mechanism of action of PRT811, key efficacy and safety findings from a phase 1 trial investigating the agent, and potential future directions with this agent in uveal melanoma and IDH-mutant high-grade glioma.

MET+ Expression May Be Predictive of Responses With Amivantamab/Lazertinib in Post-Osimertinib NSCLC

July 10th 2023

MET positivity according to immunohistochemistry showed predictive value for deriving durable responses with amivantamab plus lazertinib in patients with EGFR-mutated non–small cell lung cancer whose disease progressed on or after osimertinib and are chemotherapy naïve.

FCS Implements New Surface Guided Technology for Improved Radiation Therapy

July 10th 2023

Florida Cancer Specialists & Research Institute has introduced a new technology that provides multiple benefits for cancer patients receiving radiation therapy at the FCS Ocala Cancer Center.

Interpreting Clinical Trial Data Is Not as Simple as It May Seem

July 10th 2023

In our fast-moving world where a report of a clinically important trial finding may be simply a 60-second sound bite for both lay and medical communities, it is critical that great care must be taken that reported conclusions are understandable to all, not just the statisticians.

Trastuzumab Deruxtecan Confers Response in HER2+ Gastric/GEJ Cancer in Updated Analysis

July 10th 2023

Treatment with trastuzumab deruxtecan resulted in clinically meaningful efficacy in patients with HER2-positive gastric or gastroesophageal junction cancer following disease progression on or after a trastuzumab-containing regimen.

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9th 2023

The addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared with standard of care alone for patients with metastatic castration-resistant prostate cancer.

CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer

July 8th 2023

Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in hormone receptor–positive breast cancer, the future of antibody-drug conjugates in triple-negative breast cancer, and the importance of educating patients about their available treatment options so they can share in the decision-making process.

Equecabtagene Autoleucel Approved in China for Relapsed/Refractory Multiple Myeloma

July 7th 2023

China’s National Medical Products Administration has approved the new drug application for equecabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma who previously received 3 or more lines of therapy, including a proteasome inhibitor and an immunomodulatory drug.

Navtemadlin With Ruxolitinib Leads to SVR Benefit in TP53 Wild-Type Myelofibrosis

July 7th 2023

John O. Mascarenhas, MD, discusses the design and rationale of the KRT-232-109 trial, key findings from the trial, and potential future directions of the study.

Long-Term OS Data Confirm Pembrolizumab/Lenvatinib as a Primary Frontline Option in Advanced RCC

July 7th 2023

Thomas Hutson, DO, PharmD, expands on previously reported findings from the CLEAR study, details updated data from the final OS analysis, and emphasizes how these results support the use of this regimen as a mainstay treatment option in the frontline setting for patients with advanced RCC.

Fixed-Duration CAPTIVATE Regimen Is Effective in CLL Regardless of High-Risk Genomic Features

July 7th 2023

Treatment with fixed-duration ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia in the first-line setting elicited durable responses and sustained progression-free survival outcomes regardless of high-risk genomic features.

BLU-945 Plus Osimertinib Has Favorable Tolerability, Warrants Further Development in EGFR+ NSCLC

July 7th 2023

BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.

Fox Chase Cancer Center Welcomes Dr. Peter A. McCue

July 7th 2023

Fox Chase Cancer Center is pleased to announce the hiring of Peter A. McCue, MD, as a Professor in the Department of Pathology.

Zenocutuzumab Wins FDA Breakthrough Therapy Designation for Advanced NRG1+ NSCLC

July 7th 2023

The FDA has granted breakthrough therapy designation to zenocutuzumab for use as a potential therapeutic option in patients with advanced unresectable or metastatic, NRG1 fusion–positive non–small cell lung cancer following progression with prior systemic therapy.

Paxalisib Plus Radiation Earns FDA Fast Track Status for PI3K+ Solid Tumor Brain Metastases

July 7th 2023

The FDA has granted a fast track designation to paxalisib in combination with radiation therapy for the treatment of patients with solid tumor brain metastases harboring PI3K pathway mutations.

FDA Awards Orphan Drug Designation to Inobrodib for Multiple Myeloma

July 7th 2023

The FDA has granted orphan drug designation to inobrodib for use as a potential therapeutic option in patients with multiple myeloma.